Database Member Home
RAS Member Home
In an increasingly crowded US oncology market, it is imperative for bio-pharma companies to plan and execute their oncology portfolio launches seamlessly.
This Best Practices LLC's study equips oncology launch teams with evidence-based benchmarks around investment, staffing and timing requirements to successfully launch new oncology drugs in the U.S. market.
For further launch related queries, please contact: firstname.lastname@example.org or email@example.com
Pharmaceutical companies continue to improve the effectiveness of their managed care interactions by employing specialized medical liaisons who can speak the "payer language... (ID POP-283)
Read More »
As pharmaceutical and medical device companies improve their investigator-initiated trial (IIT) programs, it is critical to properly vet each proposal and approve the ones that demonstrate scientific merit and align with corporate objectives... (ID POP-282)
In pharma, regulatory and access restrictions have reshaped key interactions with thought leaders... (ID POP-267)
Key Opinion Leaders (KOLs) are recognized as one of the most effective avenues for building awareness in medical and scientific communities... (ID POP-253)
Pharmaceutical and life science companies rely heavily on key opinion leaders (KOLs) to improve their credibility in the marketplace... (ID PSM-235)
Pharmaceutical and medical device organizations seek strategic insights and guidance to successfully navigate the complexities of the changing healthcare landscape... (ID PSM-319)
As Medical Science Liaisons (MSLs) increasingly face restricted access to physicians and KOLs, it is important for biopharmaceutical and medical device companies to empower MSLs with new processes and tools that facilitate rapid and effective customer engagement... (ID POP-286)
The growing demand for scientific and medical data in the biopharmaceutical industry has pushed organizations to develop effective KOL engagement strategies for their field-based medical and field-based outcomes and pricing group... (ID POP-288)